Cover page & Director's Report - Central Drug Research Institute

ISSN 0972-1789Central Drug Research Institute, CSIR2010-11

THRUST AREAS OF RESEARCH1. Malaria and other Parasitic DiseasesDevelopment of new drugs/drug combinations as therapeutic interventions for malaria,leishmaniasis and filariasis;Establish novel target based drug assay protocols for identification of new leads;Knowledge generation on parasite biology and host parasite interactions.2. Reproductive Health Research, Diabetes and EnergyMetabolismDevelopment of novel agents for fertility regulation, management of post-menopausalosteoporosis, type II diabetes mellitus, hyperlipidemic condition and other endocrinedisorders through modern drug design, scientific validation of traditional remedies;Understanding pharmacological basis of actions of promising agents & existingtherapeutics and undertake basic research to generate new knowledge on reproductiveendocrinology relevant to fertility regulation, osteoporosis and diabetes.3. Tuberculosis and Microbial InfectionsSimplification and shortening of treatment for drug-sensitive tuberculosis and search ofnew treatments for MDR-TB;Development of new drugs for bacterial, fungal and viral (HIV and JEV) infections andtuberculosis.4. CVS, CNS and Related DisordersDevelopment of new target based drugs to alleviate CVS, CNS and related disorders(hypertension, dyslipidemia, atherosclerosis, thrombosis, myocardial infarction,anxiety, psychosis, dementia, stroke, stress, gastric ulcers and inflammation);Carry out excellent basic research to delineate the molecular mechanisms of thesepathologies so as to identify suitable targets for drug discovery, as well as to analyze thepossible mechanism(s) of action of the candidate drugs.5. Cancer and Related AreasCreation of appropriate platform for interdisciplinary collaborative research;Creation of knowledge base in cancer biology;Lead identification/optimization to obtain drug-like molecules.6. Safety and Clinical DevelopmentPre-clinical, clinical development and commercialization of new generation affordabledrugs for diseases of national importance and international relevance;Creation of center of excellence in the field of Clinical trials, Regulatory toxicology,Safety pharmacology, Pharmaceutics and Pharmacokinetics & metabolism andcatering to the needs of pharmaceutical industries.

2010-11Central Drug Research Institute, CSIRNRrj eafty iSysl] egkRek xka/kh ekxZ] y[kuÅ & 226 001Fax: 91 522 2623405, 2623938, 2629504Phone: 91 522 2612411-18 PABX

EDITORIAL BOARDChairman : Dr. Tushar Kanti ChakrabortyManaging Editor : Dr. A.K. GoelEditor-in-Chief : Mr. Vinay TripathiExecutive Editor : Dr. Anand P. KulkarniAssociate Editors : Dr. Sripathi Rao S. Kulkarni: Dr. Sanjeev YadavEditorial Board Members : Dr. D.N. Upadhyay: Mr. Prem PrakashCover Design : Mr. Ali KausarHindi Translation : Mrs. Neelam SrivastavaSecretarial Staff : Mr. Jitendra PatelThe information given in this document is the property of Central Drug Research Institute, CSIR, Lucknow andshould not be reproduced or quoted in any way without written permission from the Director, CDRI.Published by Dr. A.K. Goel, Deputy Director and Head, Division of S&T Management on behalf of Director, Central Drug Research Institute(Council of Scientific and Industrial Research), LucknowPrinted at Army Printing Press, 33, Nehru Road, Sadar Cantt., Lucknow. Phone: 0522-2481164

Central Drug Research Institute, CSIRHIGHLIGHTS OF ACHIEVEMENTS Product Launched for Marketing (2010) :Memory Sure (re)launchedon 17 February 2010Publications in SCI Journals (2010) : 244- Average Impact Factor : 2.894- Publications with Impact Factor >5 : 14Book Chapters (2010) : 03Patents (2010)- Filed Abroad : 10- Filed in India : 12- Granted Abroad : 06- Granted in India : 12Ph.D. Thesis Submitted (2010) : 37Contract Research Undertaken (2010) : 03Grant-in-Aid Projects Initiated (2010) : 20CSIR EMPOWER Projects Initiated : 10(2010)Total External Budgetary Resources : ` 14.42 Crore(2010-11)Budget 2010-2011 : ` 138.56 Crore(CSIR Grant-Sanctioned Estimates)Provisional data as on 01/02/2011

THE CHARTERDevelopment of new drugs and diagnostics;Cellular and molecular studies to understand disease processesand reproductive physiology;Development of contraceptive agents and devices;Systematic evaluation of medicinal properties of naturalproducts;Development of technology for drugs, intermediates andbiologicals;Dissemination of information in the field of drug research,development and production;Consultancy and development of technical manpower.

Central Drug Research Institute, CSIRCONTENTSfuns'kd dh dye lsFrom the Director's DeskPerformance ReportResearch CouncilManagement CouncilixixiiSection I: Progress in Research Projects1. Malaria and other Parasitic Diseases 12. Reproductive Health Research, Diabetes and Energy Metabolism 113. Tuberculosis and Microbial Infections 194. Cardiovascular, Central Nervous System and Related Disorders 245. Cancer and Related Areas 346. Safety and Clinical Development 37Section II: Technical Services & Facilities 45Section III: Research Output1. Publications 512. Patents 623. Papers Presented in Conferences 674. Inter Agency Linkages 735. Human Resource Development 756. Honours and Awards 78Section IV: Other Activities1. Major Events Organized 812. Diamond Jubilee Celebrations 873. Distinguished Visitors and Lectures 904. Visits by Distinguished Delegates 915. Lectures Delivered by Institute Scientists 926. Visits Abroad 947. Membership of Scientific Societies and Committees 95

vuqla/kku miyfC/k;k¡1- isVs.V~l 972- lEesyuksa esa izLrqr 'kks/k i= 1043- vUr%vfHkdj.k lac)rk 1134- ekuo lalk/ku fodkl 1165- iq#Ldkj ,oa lEeku 120vU; xfrfof/k;k¡1- izeq[k vk;ksftr dk;ZØe 1232- ghjd t;arh lekjksg 1313- vfr fof'k"V vkxqUrd ,oa O;k[;ku 1354- fof'k"V izfrfuf/k;ksa dk lh-Mh-vkj-vkbZ- vkxeu 1365- laLFkku ds oSKkfudksa }kjk fn;s x;s O;k[;ku 1376- fons'k ;k=k 1417- oSKkfud lfefr;ksa dh lnL;rk 142LVkQ 145

Central Drug Research Institute, CSIRfuns'kd dh dye lsdsUnzh; vkS"kf/k vuqla/kku laLFkku dh LFkkiuk dsghjd t;Urh o"kZ dh iwoZ la/;k ij vkids le{k o"kZ2010-11 dh okf"kZd fjiksVZ izLrqr djrs gq, eq>svR;f/kd g"kZ dk vuqHko gks jgk gSA 17 Qjojh]1951 dks Hkkjr ds rRdkyhu iz/kkuea=h ia- tokgjyky usg: }kjk fof/kor mn~?kkVu ds Ik'pkr~laLFkku us vius vfLrRo ds 60 o"kZ iw.kZ fd;s gSaAlh-Mh-vkj-vkbZ- dh LFkkiuk ,d ,slh ifjdYiukij vk/kkfjr gS tks ekuo tkfr dks csgrj Hkfo";]mUur thou vkSj ekudksa ds vuq:Ik LokLF; iznkudjus ds fy;s dk;Zjr gSA ge bl vkn'kZ ds lkFkdk;Z djrs gSa fd lQyrk dsoy lfØ;rk ls ughaizkIr dh tk ldrh gS cfYd Hkfo"; dh :ijs[kkrS;kj djrs le; dYiuk vkSj nwjn`f"V dks /;ku esaj[kuk vko';d gS vkSj blds fy;s ge foKku dksO;ogkfjd cukus vkSj mls yksxksa rd igq¡pkus dsfy;s uSfrdrk vkSj bZekunkjh ds mPpre Lrj dkscuk, j[kus ds izfr opuc) gaSA lkFk gh foKku dksizHkkoh cukus] izlkfjr djus] bldh mRikndrk vkSj{kerk esa lq/kkj dj ewY;&izHkkoh mRikn vkSj lsok,ayksxksa rd igq¡pkus] n{k ,oa lqfo/kktud miHkksDrk lsok vkSj mlds }kjk ns'k dh laiw.kZ mUufr vkSj fodkl esa ;ksxnku djus dsfy;s l{ke izkS|ksfxdh dks vf/kd ls vf/kd Åij ykuk gSAfjiksfVZax o"kZ esa gekjh izxfr dh jkg vklku ugha FkhA lqfu;ksftr fodkl vkSj o`f) ds eqn~nksa rd igq¡pus ds fy;s ewyHkwrvko';drkvksa dks igpkuuk gekjs fy;s ,d pqukSrhiw.kZ dk;Z FkkA vius vuqla/kku fØ;kdykiksa ij /;ku dsfUnzr djus dsvfrfjDr ge u, ifjlj esa viuh mRd`"Vrk dks uohu vkSj vR;k/kqfud lqfo/kk dh vksj 'kh?kz ls 'kh?kz LFkkukarfjr djus ds izfropuc) gSa vkSj dk;Z fu"iknu rFkk lsok ds Js"B ekudksa ds ek/;e ls miHkksDrkvksa dh vkdka{kkvksa vkSj vis{kkvksa dk lkeukdjus ds fy;s mPp izkS|ksfxdh dks /;ku esa j[kdj fof/kd] Ik;kZoj.kh; vkSj uSfrd izfØ;kvksa ds fofufnZ"V ekudksa esa yxs jgdjvius nkf;Ro iwjs djrs jgsaxsA gedks mPp izkS|ksfxdh] vfHkdYiuk vkSj vfHk:fp ds iz;ksx dks /;ku esa j[krs gq, dk;Z vkSjlsokvksa ds Js"B ekudksa ds ek/;e ls lcdh vkdka{kkvksa vkSj vis{kkvksa dks iwjk djuk gSA izfrHkk ds fy;s volj vkSj LFkkfirekU;rkvksa dks pqukSrh nsrs gq,] fcuk fdlh izfØ;kRed izfrca/k ds ge jpukRedrk dks izksRlkgu nsus ds fy;s opuc) gSaA bldsvfrfjDr ge oSf'od Lrj ij mHkjrh gqbZ foKku laca/kh pqukSfr;ksa vkSj jk"Vªh; vkdka{kkvksa ds vuq:Ik viuh 12oha iapo"khZ;;kstuk rS;kj djus ds fy, opuc) gSa ftlds fy;s gesa bZekunkjh vkSj xaHkhjrkiwoZd dke djuk gS ftlls vxys ikap o"kksZa dsfy;s ,d ,slh lQy ;kstuk rS;kj fd;k tkuk lqfuf'pr fd;k tk lds tks laLFkku dks u, ifjlj esa fufoZ?u ys tkus esa ennxkjfl) gks ldsA

izfrosnu dk o"kZ ?kVuk iz/kku jgk gSA lh-Mh-vkj-vkbZ- ghjd t;Urh lekjksg dk 'kqHkkjaHk ;kstuk vk;ksx ds lnL; vkSjHkkjrh; varfj{k vuqla/kku laxBu ds HkwriwoZ v/;{k MkW- ds- dLrwjhjaxu }kjk fd;k x;kA rRi'pkr~ cgqr ls O;k[;ku]lsfeukj] laxks"Bh] izf'k{k.k dk;ZØe] vUrjkZ"Vªh; dk;Z'kkyk bR;kfn dk vk;kstu fd;k x;kAfpfdRlk vkSj izfØ;k jlk;u izHkkx esa 2003 la'ysf"kr ;kSfxdksa dk la'ys"k.k fd;k x;k vkSj mudks tSfod ijh{k.k ds fy;sizLrqr fd;k x;kA tks lfØ; ik, x, mudks yhM vkWfIVekbts+'ku vkSj vuqorhZ v/;;u ds fy;s izLrqr fd;k x;kA ouLifrfoKku izHkkx us ns'k ds fofHkUu Hkkxksa ls 39 u, ikni lkexzh dk ,d=hdj.k fd;kA buesa ls 27 uewuksa dk izek.khdj.k vkSjvfHkys[ku fd;k x;k x;k rFkk budks vuqorhZ dk;Z ds lkFk&lkFk laLFkku ds izkFkfed tSfod ijh{k.k dk;ZØe ds fy;s izLrqrfd;k x;kA N% ikS/kksa dks Hkkjh ek=k esa ,d= fd;k x;kA leqnzh ewy ds uewuksa esa 15 lgHkkxh dsUnzksa ls 337 u, uEkwus vkSj 164iqujko`Rr uewus izkIr gq, vkSj vk¡dM+ksa ds izys[ku ds Ik'pkr~ mudh fpfg~Ur fØ;k&dykiksa dh iqf"V vkSj lkekU; tSfod ijh{k.kds fy;s lac) tho oSKkfudksa dks forfjr dj fn;k x;kA geus lHkh ekspksZ ij egRoiw.kZ mUufr dh gS tks vf/kd la'kksf/kr izHkkorRo 2.89 lfgr 244 izdk'kuksa vkSj 12 Hkkjrh; vkSj 10 fons'kh isV.V Qkby fd;s tkus vkSj 12 Hkkjrh; vkSj 6 fons'khisV.V Lohd`fr iznku fd;s tkus ls Li"V gSA bl o"kZ 39 fo'ofo|ky;ksa ds 178 fo|kfFkZ;ksa dks fofHkUu fo"k;ksa esa izf'k{k.k iznkufd;k x;k vkSj fofHkUu fo|kfFkZ;ksa us ih-,p-Mh- fMxzh iznku fd;s tkus ds fy;s viuk 'kks/k izca/k izLrqr fd;kAfjiksfVZax o"kZ ds nkSjku vusd lg;ksfx;ksa dks laiw.kZ fo'o dh fofHkUu ,tsafl;ksa ls ;qok oSKkfud iqjLdkj] izfrf"Br lfefr;ksa lsQsyksf'ki] ind rFkk fons'kh lgk;rk izkIr gqbZA jk"Vªh; rFkk varjkZ"Vªh; lEesyuksa esa cgqr ls Nk=ksa dks iqjLdkj vkSj lEeku izkIrgq,A eSa mu lHkh dks c/kkbZ nsrk gw¡ vkSj vk'kk djrk gw¡ fd bl izdkj dk ewY;kadu nwljkssa dks Hkh csgrj miyfC/k ds fy;s var%izsfjr djsxkA eSa mu lHkh LVkQ lnL;ksa dks muds ewY;oku lg;ksx vkSj ;ksxnku ds fy;s /kU;okn nsrk gw¡ vkSj vk'kk djrk gw¡ fdos ,d Uk;k fo'oLrjh; dsUnzh; vkS"kf/k vuqla/kku laLFkku cukus ds fy;s vf/kdkf/kd ifjJe djuk tkjh j[ksaxsA eSa nq%[k ds lkFkbl o"kZ vius 4 lg;ksfx;ksa ds fu/ku dh lwpuk ns jgk gw¡A eSa mudh vkRek dh 'kkafr ds fy;s izkFkZuk djrk gw¡AeSa miHkksDrk lsok esa lq/kkj ds }kjk fodkl ds y{; dks izkIr djus vkSj gj igyw ls laLFkku dk dk;Z pykus ds fy;s ewY;oku;ksxnku gsrq vius oSKkfudksa] rduhf'k;uksaa] vk/kkfjd ,oa iz'kklfud LVkQ ds ln~Hkkoukiw.kZ] lg;ksxkRed leFkZu dh ljkgukdjrk gw¡A viuh vksj ls ge ikjn'khZ] izfr;ksfxrkRed vkSj LoLFk vuqla/kku iz;ksxksa gsrq dk;Z djus dh izfrKk djrs gSa vkSj vk'kkdjrs gSa fd gekjs vuqla/kku vkSj fodkl ls vf/kd ls vf/kd yksx ykHk mBk,axsA var esa] eSa var%dj.k ls lh-,l-vkbZ-vkj- dksmuds lg;ksx vkSj lgk;rk ds fy;s rFkk jk"Vªh;@vUrjkZ"Vªh; vuqnku iznkrk ,tsafl;ksa] fjlpZ@eSustesaV dkmfUly ds lnL;ksavkSj bysDVªkWfud rFkk fizUV ehfM;k dk muds ewY;oku lq>koksa vkSj ijke'kZ gsrq vkHkkj izdV djrk gw¡A¼rq"kkj dkfUr pØorhZ½Qjojh 17, 2011

Central Drug Research Institute, CSIRFROM THE DIRECTOR'S DESKn the eve of Diamond Jubilee YearO of this prestigious institution, itgives me immense pleasure inpresenting before you our AnnualReport 2010-11. The Institute,formally inaugurated on February 17,1951 by the then Prime Minister ofIndia Pt. Jawaharlal Nehru, hascompleted 60 years of its existence.CDRI is founded on a vision whichseeks to usher in better tomorrow byproviding mankind an improved qualityof life and health standards. We arecommitted to work with a motto thatsuccess cannot be measured byaccomplishments alone but by visionand foresight to chart our path for thefuture. For that to happen, we maintainthe highest level of ethics and integrityin practicing and communicating ourscience and optimally leveragetechnology to increase penetration,improve productivity and efficiency,deliver cost-effective products and services, provide faster, efficient and convenient customerservice and thereby, contribute to the overall growth and development of the country.The reporting year was not an easy one; as recognizing the basic needs to approach the issue ofplanned development and growth was a challenging task before us. Besides concentrating on ourresearch activities, we are committed to shift at the earliest to the world class state-of-the-artfacility in the new campus and keep discharging our obligations by adhering to specified norms oflegal, environmental and ethical practices. However, we have to keep in mind the use of high-endtechnology, design and aesthetics that meet aspirations and expectations of all through superiorstandards of performance and services. We are pledged to foster creativity without proceduralrestrictions, open to talent and to challenge established ideas. Besides, we are committed tothprepare our 12 five year plan in accordance with the emerging global scientific challenges andnational aspirations, for which we have to work sincerely and earnestly, ensuring to makeinfallible plans for the next five years commensurable for smooth transition to the new campus.The year under report has been eventful. CDRI Diamond Jubilee Celebrations were initiated byDr. K. Kasturirangan, Member, Planning Commission and Former Chairman, ISRO. Ever since

then, several lectures, seminars, symposia, training programs, international workshop, etc.were held.A record number of 2003 synthetic compounds were synthesized in the Medicinal and ProcessChemistry Division and submitted for biological screening. Those found active, are beingpursued further for lead optimization and follow-up studies. Botany Division collected 39 newplant materials from different parts of the country. Of these, 27 samples were authenticated,documented and submitted for follow-up as well as in primary biological screening program ofthe Institute. Six plants were collected in bulk quantity. With regard to samples of marine origin,337 new samples and 164 repeat samples were received from 15 participating centers and afterdocumentation of data; they were distributed to the concerned biologists for confirmation ofidentified activities and general biological screening. We made significant progress on all frontswhich is evident from 244 publications with much improved average impact factor 2.89 and filingof 12 Indian & 10 foreign patents and grant of 12 Indian & 6 foreign patents. This year, 178students from 39 universities were imparted training in different disciplines and several studentssubmitted their thesis for the award of Ph.D. degree.During the reporting period, several colleagues received recognitions from different agenciesfrom all over the globe, including young scientist awards, fellowships from prestigious societies,medals and foreign grants. Number of research scholars received awards and recognitions innational and international conferences. I congratulate all the winners and hope that suchappreciations would inspire others to achieve even better. I thank all the staff members for theirvaluable support and contributions and hope that they would continue to work even harder tobuild a new world-class CDRI. I report with sorrow the sad and untimely demise of 4 colleaguesthis year. I pray that their souls rest in peace.I place on record the sincere appreciation, cooperation and support received from ourexperienced scientists, technicians, infrastructural and administrative staff for their valuablecontributions in every aspect of the Institute's operation and for targeting profitable growth andthereby improve customer services. On our part, we pledge to work for transparent, competitiveand healthy research practices and hope that more and more people will be benefited by our R&Dworks. Last, but not the least, I whole heartedly acknowledge the support, help and guidancefrom CSIR, all national and international funding agencies, Members of Research/ManagementCouncil, electronic and print media for their valuable suggestions and advice.(T.K. Chakraborty)February 17, 2011

New Inter-Agency Projects Initiated2518192332015101155121212231 1 12112955062168633122006 2007 2008 2009 2010DBT DST ICMR DRDO Foreign Industry OthersPerformance Report

Central Drug Research Institute, CSIRPerformance ReportThe year 2010-11 is the Diamond Jubilee Year of CDRI. Housed in the historicChattar Manzil, an old palace of the Nawabs of Awadh, the institute was formallyinaugurated on 17 February 1951 by the then Prime Minister of India, PanditJawahar Lal Nehru. The institute was set up with the objective to carry outbiomedical research in all its aspects and to build a strong scientific andtechnological base for the development of drug and pharmaceutical industry inthe country. Initially, it started with five R&D divisions and a skeletal staff ofscientists and technicians. Today, the institute has emerged as an internationallyrecognized centre for biomedical research and has a distinction of having all theinfrastructural facilities for development of new drugs from conceptual tocommercialization stage. In the persuit of new drugs and technologies, CDRI has discoveredand developed 12 drugs and more than 100 process technologies. Several of its products were commercialized successfully andcurrently four products are in market. The antimalarial drugs Arteether and Artemether are being marketed in more than 30countries of Asia and African continents. Memory Sure is being marketed in more than 8 countries. Centchroman, the only antiimplantationagent approved for clinical use in the world, is being marketed under a brand name Saheli. It is a widely endorsedcontraceptive pill in India.thOn 14 July, 2010, Dr. K. Kasturirangan, Member Planning Commission and FormerChairman, ISRO inaugurated the CDRI Diamond Jubilee Celebrations byunveiling of Diamond Jubilee Logo and Poster. To commemorate the year,several mini symposia, workshops, lectures by eminent scientists, across theglobe, were organized. The institute continued to make steady progress in allaspects during the year. A brief summary of S&T performance of the instituteduring 2010-11 is presented below:Memory Sure (re)Launched on 17 February 2010Bacosides Enriched Standardized Extract of Bacopa (BESEB)BESEB – Single plant based natural memory enhancer from Bacopa monniera;Licensed to Lumen Marketing Co., Chennai for extensive marketing in India through ZaarDistributors Pvt. Ltd., Delhi;For the prevention & early treatment of dementia, particularlyChildren suffering from Attention Deficit Hyperactivity Disorder,Elderly persons with Age Associated Memory Impairment,for those with emotional stress from relationship or stress, tension, anxiety fromwork/study.Clinical Trials on BESEB Conducted byCDRI-CSIR, Lucknow, India,Lumen: Australia (Swinburne University ofTechnology’s Brain Sciences Institute &University of Wollongong)The product is being exported to followingcountries:New Zealand & Australia* - Keenmind,Membac,Malaysia, Philippines & Singapore - MemoPlus Gold,France & Germany - Memory Perfect.*First drug approved by “Therapeutic Goods Authority,Australia” for memory enhancing.

Performance ReportCandidate Drugs under Advance Stages of DevelopmentDiseases /DisordersCandidateDrugsEfficacy Clinical Status Licensees &CollaboratorsLiver Disorder Picroliv Hepatoprotective Phase III clinical trial completed at CSSMU,Lucknow and Seth GS Medical College & KEMHospital Mumbai.DIL, MumbaiDyslipidemia 80-574 +AtorvastatinAnti-dyslipidemicPermission awaited from DCG(I) for extendedphase III clinical trial.CadilaPharmaceuticalsLtd., AhmedabadMalaria 97-78 Antimalarial Phase-I single dose clinical study completed.DCG(I) approval received for single dosepharmacokinetic study in healthy volunteers asper revised protocol.Diabetes CDR 134D123 Antihyperglycemic Phase-I single & multiple dose studies completed;Report submitted to AYUSH; and has beenreferred to Extra Ayurvedic PharmacopiaCommittee for inclusion.IPCA Labs.,MumbaiTVC Sky Shop Ltd.,MumbaiDiabetes &DyslipidemiaCDR 134F194 Antihyperglycemic Modified dossier submitted to DCG(I) – INDCommitteeTVC Sky Shop Ltd.,MumbaiOsteoporosis 99-373 Anti-osteoporotic Plan and protocol of phase I clinical trial has beenapproved by DCG(I).Malaria 99-411 Antimalarial Pre-clinical data is under compilation for INDsubmission.Open for licensingIPCA Labs., MumbaiStrokeHerbalMedicamentNeuroprotective IND application is under preparation. Themis MedicareLtd., MumbaiDiseases /DisordersLeadCompoundPotential New LeadsEfficacy Status Licensees &CollaboratorsOsteoporosis S-007-1500 Fracture healing Single dose toxicity study in rat and mice by oralroute completed. Compound found safe at 50and 100 mg/kg body weight respectively.Osteoporosis 914-K058 Osteogenic Mode of action elucidated; 5 mg/kg daily oraldose stimulated bone formation comparable todaily injection of parathyroid hormone.Under negotiationUnder negotiationBone FractureRepair4669 Bone anabolicagentEfficiency established in experimental models (invitro / in vivo).Open for licensingDiabetes &Dyslipidemia4655-K09 Antidyslipidemic Wide dosage range efficacy established. Open for licensingThrombosisS-002-333 &S-007-867AntithromboticEfficacy and mechanism of action established;Single dose toxicity study in rat by oral routecompleted and both the compounds found safeat 600 mg/kg body weight.Under negotiationContraception S-003-296 Spermicidal Efficacy established; Indian patent granted. Open for licensingCancer S-009-131 Anti-cancer IC 50 < 3 µg/mL for cervical cancer cell line. Nontoxicfor normal cell and breast cancer (SI >10).Tuberculosis S-006-830 Antituberculosis MIC < 3 µg/mL for Mtb H37Rv. Efficacyestablished in vitro & ex vivo.Open for licensingOpen for licensingiiCDRI-CSIR

Performance ReportTotal No. of Publications300250197233 236297244*2001501005002006 2007 2008 2009 2010Impact Factor-wise No. of Publications 2010*Average Impact Factor2.89*2.9IF 3-4: 662.72.592.57IF 4-5: 152.52.37IF >5: 14IF 2-3: 902.32.13IF

Performance ReportIndian Patents*1615FiledGranted141210811810812 12 126445202006 2007 2008 2009 2010Foreign Patents*3030FiledGranted2520151015211112191020106502006 2007 2008 2009 2010Global Distribution of Granted Patents of CDRI*Provisional data as on 03.02.2011ivCDRI-CSIR

Performance ReportNew Inter-Agency Projects Initiated25201510502006 2007 2008 2009 2010DBT DST ICMR DRDO Foreign Industry OthersExternal Cash Flow from Government AgenciesExternal Cash Flow from Foreign AgenciesRs. in lakh180015001200900600300954.7561287.8421090.0191628.9521242.816*Rs. in lakh200180160140120100806040205.12517.12577.485180.07962.793*02006-07 2007-08 2008-09 2009-10 2010-1102006-07 2007-08 2008-09 2009-10 2010-11External Cash Flow from IndustriesLab Reserve Fund Generated3028.20300261.189Rs. in lakh25201510514.804.8841.0047.167*Rs. in lakh24018012060187.440111.734215.649128.765*02006-07 2007-08 2008-09 2009-10 2010-1102006-07 2007-08 2008-09 2009-10 2010-11* Provisional data as on 03.02.2011Annual Report 2010-11v

Performance ReportBUDGET2010-2011 (Sanctioned Estimates)*(Rs. in lakh)HeadsCSIR Grant(A) RecurringPay and Allowances 3668.400Contingencies 254.650HRD 4.000Lab Maintenance 150.000Staff Quarter Maintenance 15.000Chemicals and Consumables 501.110Sub-Total 4593.160(B) CapitalWorks and Services 65.000Apparatus and Equipments 1000.000Office Equipments, Furniture and Fittings 7.000Library Books and Journals 225.000Staff Quarter (Construction) 25.000Sub-Total 1322.000Total (A+B) 5915.160(C) SIP/NWP/IAP/FAC/CMM/SMM Projects 7941.560Grand Total (A+B+C) 13856.720* Provisional data as on 03.02.20112009-2010 (Actual Expenditure)Heads CSIR Grant L.R.F.(A) RecurringPay and Allowances 4046.092Contingencies 221.000 35.298HRD 4.000Lab Maintenance 150.000 14.112Staff Quarter Maintenance 14.000Chemicals and Consumables 405.260 6.439Sub-Total 4840.352 55.849(B) CapitalWorks and Services/ Electrical Installations 20.000 34.424Apparatus and Equipments/ Computer Equipments 478.000 5.779Office Equipments, Furniture and Fittings 9.021Library Books and Journals 215.000Staff Quarter (Construction) 12.258Sub-Total 734.279 40.203Total (A+B) 5574.631 96.052(C) SIP/NWP/IAP/FAC/CMM/SMM Projects 7358.020Grand Total (A+B+C) 12932.651 96.052viCDRI-CSIR

Performance ReportTotal Budget (CSIR Grant)*1400013028.70313856.720 #12000100009810.5758876.226Rs. in lakh800060004000200002007-08 2008-09 2009-10 2010-11*Includes Regular Budget, Plan Projects (CMM/SMM/SIP/NWP/IAP/HCP/OLP/MLP), New CDRI Budget and expenditure against LRF.#Sanctioned Estimates as on 3/2/2011Total External Budgetary Resources25002052.880Rs. in lakh2000150010001571.0401280.2421441.541*50002007-08 2008-09 2009-10 2010-11* Provisional data as on 03.02.2011New Facilities EstablishedAgilent 2100 BioanalyzerThe Agilent2100 bioanalyzer is amicro fluidics-basedplatform for sizing,quantification andquality control of DNA,RNA, proteins andcells on a singleplatform. Results aredelivered within 30-40 minutes in automated, highquality digital data.Agilent 6520, Accurate-Mass Q-TOF MassSpectrometer LCMS systemQ TOF LCMS/MS isa high resolution massspectrometer with ESI andAPCI ion source, whichprovides exact mass up to3000Da in ESI and 1000Da in APCI. It also has MS/MS facility for identification and characterization of smallmolecules. Liquid Chromatography system attached withQ TOF Mass spectrometer is an added facility forseparation of molecules.Annual Report 2010-11vii

Performance ReportManpowerTotal StaffTotal Staff: Male - Female RatioTech. Gr. I133Tech. Gr. II113Tech. Gr. III114Male527Scientist148Administration135Female116Designation-wise Number of ScientistsAverage Age of ScientistsScientist EI22Scientist C3411Scientist BScientist EII29Scientist F33Scientist G19Scientist EI42Scientist C34Scientist BScientist EII3249Scientist F54Scientist G57Area-wise Strength of ScientistsResearch Fellows and Project AssistantsBiological Sciences69JRF166ChemicalSciences25TechnicalServices30Safety &Pre-clinicalSciences24Proj. Asst.133SRF206QHF-1RA-6Data as on 01.01.2011viiiCDRI-CSIR

Performance ReportWe Welcome Newly Recruited ScientistsRavi Sankar Ampapathi, M.Sc., Ph.D.Scientist Gr. IV (3)Sophisticated Analytical InstrumentationFacilityManjunatha Prabhu, B.H., M.V.Sc.Scientist Gr. IV (2)Laboratory Animals DivisionMaddi Sridhar Reddy, M.Sc., Ph.D.Scientist Gr. IV (3)Medicinal and Process ChemistryRajesh Kumar Jha, M.Sc., Ph.D.Scientist Gr. IV (2)EndocrinologyArunava Dasgupta, M.Sc., Ph.D.Scientist Gr. IV (3)MicrobiologyVivek Vidyadhar Bhosale, M.B.B.S., M.D.Scientist Gr. IV (2)Clinical & Experimental MedicineJagadeshwar Reddy Thota, M.Sc., Ph.D.Scientist Gr. IV (3)Sophisticated Analytical InstrumentationFacilityMrigank Srivastava, M.Sc., Ph.D.Scientist Gr. IV (2)ParasitologySurender Reddy, M.Sc., Ph.D.Scientist Gr. IV (2)PharmaceuticsSanjeev Yadav, M.Sc., Ph.D.Scientist Gr. IV (1)S&T ManagementDipankar Koley, M.Sc., Ph.D.Scientist Gr. IV (2)Medicinal and Process ChemistryHimangsu Kousik Bora, M.V.Sc.Scientist Gr. IV (1)Lab Animals DivisionVineeta Tripathi, M.Sc., Ph.D.Scientist Gr.IV (2)BotanyAbhishek Kumar, M.C.A.Scientist Gr. IV (1)Computer DivisionShubha Shukla, M.Sc., Ph.D.Scientist Gr. IV (2)PharmacologyNeha Topno, M.Sc.Scientist Gr. IV (1)MicrobiologyAnnual Report 2010-11ix

Performance ReportSETTING UP OF WORLD-CLASS DRUG RESEARCH INSTITUTEThe New CDRI Campus, spread across approximately 61 acres of land, houses R&D Laboratories, support services(Animal House, SAIF, Lab Engineering, Administration, etc.). The campus will also provide residential accommodation to itsemployees, hostel facilities to research fellows and other amenities. The project is in advanced stage of completion and itis expected that shifting activities will begin by second quarter of 2011.xCDRI-CSIR

Research Council(April 2010 – March 2013)ChairmanProf. N.K. GangulyFormer Director General, ICMR,Distinguished Biotechnology Fellow & Advisor,Translational Health Science & Technology InstituteC/o National Institute of ImmunologyAruna Asaf Ali MargNew Delhi – 110067MembersDr. A. SuroliaDirectorNational Institute of ImmunologyAruna Asaf Ali MargNew Delhi - 110067Dr. K. NagarajanCorporate AdvisorHikal Ltd., R & D CentreKalena Agrahara Bannerghatta RoadBangalore – 560076Dr. Shekhar C. MandeStaff ScientistCentre for DNA Fingerprinting and DiagnosticsECIL Road, NacharamHyderabad- 500076Prof. K.N. GaneshDirectorIndian Institute of Science Education and Research900, NCL Innovation ParkDr. Homi Bhabha RoadPune- 411008Dr. R. NagarajScientistCentre for Cellular and Molecular BiologyUppal RoadHyderabad- 500007Dr. Bhaskar SahaScientistNational Centre for Cell ScienceGaneshkhindPune- 411007Dr. M.D. NairA-11 Sagarika No. 153rd Seaward Road, Valmiki NagarChennai - 600041Agency RepresentativeDr. (Ms.) Deepali MukherjeeChief ECDIndian Council of Medical ResearchPost Box No. 4911, Ansari NagarNew Delhi- 110029DG’s NomineeDr. Rajesh S. GokhaleDirectorInstitute of Genomics and Integrative BiologyUniversity Campus, Mall RoadDelhi- 110007Sister LaboratoryDr. Ram RajsekharanDirectorCentral Institute of Medicinal and Aromatic Plants,P.O. CIMAPLucknow – 225015Cluster DirectorProf. Siddhartha RoyDirectorIndian Institute of Chemical Biology4, Raja SC Mullick Road, JadavpurKolkata- 700032DirectorDr. Tushar Kanti ChakrabortyDirectorCentral Drug Research InstituteLucknow – 226001Permanent InviteeHead or his NomineePlanning & Performance DivisionCouncil of Scientific & Industrial ResearchAnusandhan Bhawan, 2, Rafi MargNew Delhi - 110001SecretaryDr. S.B. KattiScientistCentral Drug Research InstituteLucknow – 226001Annual Report 2010-11xi

Performance ReportManagement Council(January 2010 - December 2011)ChairmanDr. T.K. ChakrabortyDirectorCentral Drug Research InstituteLucknow – 226001MembersDr. K.C. GuptaDirectorIndian Institute of Toxicology ResearchLucknow – 226 001Dr. B. KunduScientist Gr. IV(6)Division of Medicinal & Process ChemistryCDRI, Lucknow – 226001Dr. S.P.S. GaurScientist Gr. IV(6)Clinical & Experimental MedicineCDRI, Lucknow – 226001Dr. Vinod BhakuniScientist Gr. IV(6)Molecular & Structural Biology DivisionCDRI, Lucknow – 226001Dr. (Mrs.) Saman HabibScientist Gr. IV(4)Molecular & Structural Biology DivisionCDRI, Lucknow – 226001Dr. Mohd. Imran SiddiquiScientist Gr. IV(3)Molecular & Structural Biology DivisionCDRI, Lucknow – 226001Mr. Karunesh RaiTechnical Officer Gr. III(5)Division of Laboratory AnimalsCDRI, Lucknow – 226001Controller of Finance & Accounts /Finance & Accounts OfficerCDRI, Lucknow – 226001Member – SecretaryController of Administration /Administration OfficerCDRI, Lucknow – 226001AnnouncementCDRI Award 2011The prestigious CDRI Award for Excellence in Drug Research for the year 2011 in LifeSciences has been awarded to Dr. Shantanu Chowdhury, IGIB, New Delhi for his work on“Genome wide predictions of G-quadruplex as promising drug targets” and in Chemical Sciencesthe award has gone to Dr. Gangadhar J. Sanjayan, NCL, Pune for his work on “Design anddevelopment of artificial proteins scaffolds which may be of considerable use in interveningvarious protein-protein interactions and cell membrane interactions”.Our heartiest congratulations to both the awardees. The felicitation ceremony will be heldon 26 th September 2011.xiiCDRI-CSIR